Teleflex

Teleflex, Inc. provides medical technology products which enables healthcare providers to improve patient outcomes and enhance patient and provider safety. The firm designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It operates through the following business segments: Americas, EMEA (Europe, the Middle East and Africa), Asia (Asia Pacific) and OEM. The Americas segment engages in the sales of interventional urology products. The EMEA engages in the sales of urology products. The Asia segment designs, manufactures and distributes medical devices primarily used in critical care, surgical applications and cardiac care and generally serves hospitals and healthcare providers. The OEM segment designs, manufactures and supplies devices and instruments for other medical device manufacturers. The company was founded in 1943 and is headquartered in Wayne, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teleflex reports Q4 growth amidst challenges, eyes revenue acceleration

Teleflex's Q4 performance showed resilience with revenue growth and strategic acquisitions. While facing challenges like supply chain disruptions and UroLift revenue decline, the company is focused on margin expansion and disciplined growth. Opportunities lie in revenue acceleration, international expansion, and leveraging high-growth product categories.

Teleflex reports robust Q1 earnings, eyes growth amid challenges

Teleflex's Q1 2023 results reflect strong performance and strategic focus on sustainable growth, supported by geographic revenue growth and product category contributions.
While facing challenges in specific product lines and supply chain issues, the company maintains a disciplined approach to deals and cost management.
Opportunities lie in revised revenue guidance, product performance, and market improvements, positioning Teleflex for continued success in 2023.

Teleflex reports revenue growth and strategic acquisitions drive future outlook

Teleflex revised its 2023 financial guidance with revenue growth of 5.5% to 6.25% and adjusted EPS of $13 to $13.60. Despite challenges in certain product segments, the company remains confident in achieving its Long Range Plan growth objectives. The focus on integrating acquisitions like Palette and leveraging high-growth products positions Teleflex for continued success.

Teleflex reports robust Q3 results, eyes growth amidst challenges

Teleflex's Q3 performance reflects revenue and EPS growth, driven by operational improvements.
Despite challenges from GLP-1 impact and tax rate increases, the company remains optimistic.
Opportunities lie in market expansion, M&A activities, and product uniqueness strategies.
Overall, Teleflex's strong financials and strategic initiatives position it for continued growth.

Teleflex reports solid 2023 performance, eyes growth in Urology market

Teleflex's 2023 performance showed revenue growth and strong cash flow, with guidance for 2024 indicating continued growth and margin targets.
Despite challenges like declining EPS and recall impacts, the company aims for high EPS growth and sees opportunities in new markets and product expansions.
Confidence in meeting targets, pursuing strategic initiatives, and navigating market challenges position Teleflex for growth and profitability in the coming years.
Balancing financial performance with strategic investments and operational improvements will be key for Teleflex to capitalize on growth opportunities and overcome challenges.

Teleflex reports solid Q1 performance, eyes growth through acquisitions

Teleflex's Q1 2024 performance was solid, with revenue growth, margin expansion, and strong cash flow. Despite challenges like market multiples and recall impacts, the company is focused on growth opportunities and disciplined acquisitions to drive future success.

Teleflex reports solid Q2 growth, eyes M&A and product innovation

Teleflex's Q2 performance reflects steady growth, driven by strong results in key segments and product categories.
Despite challenges in certain areas, the company's strategic initiatives, including acquisitions and product innovation, position it well for future success.
With a focus on revenue growth, operational efficiency, and shareholder value, Teleflex is poised to capitalize on opportunities and navigate challenges effectively.

Teleflex reports solid Q3 earnings, eyes growth amid challenges

Teleflex's Q3 2024 performance showcased revenue growth, margin improvement, and strategic acquisitions driving increased revenue guidance for the year.
While facing challenges in specific product categories, the company's focus on innovation, market expansion, and financial strength positions it well for future growth.
Opportunities in expanding markets, disciplined capital allocation, and strong cash flow generation underscore Teleflex's resilience and potential for sustained success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teleflex, Inc. provides medical technology products which enable healthcare providers to improve patient outcomes and enhance patient and provider safety. It operates through the following business segments: Americas, EMEA (Europe, the Middle East and Africa), Asia (Asia Pacific) and OEM. The Americas segment engages in the sales of interventional urology products. The EMEA engages in the sales of urology products. The Asia segment designs, manufactures and distributes medical devices primarily used in critical care, surgical applications and cardiac care and generally serves hospitals and healthcare providers. The OEM segment designs, manufactures and supplies devices and instruments for other medical device manufacturers. The company was founded in 1943 and is headquartered in Wayne, PA.

Company Also Announces Milestone of 350,000 UroLift® System Minimally Invasive Procedures Globally Company Also Announces Milestone of 350,000 UroLift® System Minimally Invasive Procedures Globally

Teleflex Celebrates June Men's Health Month with Launch of UroLift® Patient Ambassador Program

WAYNE, Pa., May 20, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical devices, will provide an update on its business and address its 2023-2025 business growth strategy and financial goals during its 2022 Analyst & Investor Day today in New York City. A live webcast of the event presentations will begin at 10:00 a.m. ET and the accompanying presentation materials will be available at that time on the Company's web site at teleflex.com.

Teleflex Hosts 2022 Analyst & Investor Day

Will expand patient access to BPH treatment Will expand patient access to BPH treatment

Teleflex Announces Regulatory Clearance for its UroLift® System in China for the Treatment of Benign Prostatic Hyperplasia (BPH)

WAYNE, Pa., May 18, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today has announced that it received Health Canada approval for the MANTA® Vascular Closure Device – the first commercially available biomechanical vascular closure device designed specifically for large bore femoral arterial access site closure.1 This approval marks an important milestone in the regulatory plan to expand the availability of the MANTA® Device globally and provides access to another uniquely designed device from Teleflex to Canadian clinicians.

Teleflex Announces Health Canada Approval of MANTA® Vascular Closure Device

Product demonstrations and educational presentations underscore the company's leadership in advancing care for patients with benign prostatic hyperplasia (BPH) Product demonstrations and educational presentations underscore the company's leadership in advancing care for patients with benign prostatic hyperplasia (BPH)

Teleflex Announces Full U.S. Commercial Launch of the UroLift® 2 System and UroLift ATC ® Advanced Tissue Control System

WAYNE, Pa., May 02, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced that the Company will host an Analyst & Investor Day on Friday, May 20, 2022 in New York City. Liam Kelly, Chairman, President and CEO, will be joined by members of the Company's Leadership Team and Expert Panelists. A live webcast of the event presentations will begin at 10:00 a.m. ET.

Teleflex to Host Analyst & Investor Day on May 20, 2022

Teleflex (TFX) exhibits year-over-year growth across the Americas, EMEA and Asia regions at CER in the first quarter.

Teleflex's (TFX) Q1 Earnings Top Estimates, Margins Down

Teleflex Incorporated (NYSE:TFX ) Q1 2022 Earnings Conference Call April 28, 2022 8:00 AM ET Company Participants Lawrence Keusch - VP, Investor Relations and Strategy Development Liam Kelly - Chairman, President and Chief Executive Officer Thomas Powell - Executive Vice President and Chief Financial Officer Conference Call Participants Jayson Bedford - Raymond James Cecilia Furlong - Morgan Stanley Shagun Singh - RBC Capital Markets Larry Biegelsen - Wells Fargo Matthew Mishan - KeyBanc Richard Newitter - Truist Mike Matson - Needham and Company Operator 00:04 Good morning, ladies and gentlemen, and welcome to the Teleflex First Quarter 2022 Earnings Conference Call. At this time, all participants have been placed in listen-only mode.

Teleflex Incorporated (TFX) CEO Liam Kelly on Q1 2022 Results - Earnings Call Transcript

WAYNE, Pa., April 28, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the first quarter ended March 27, 2022.

Teleflex Reports First Quarter Financial Results And Full Year Outlook

WAYNE, Pa., April 26, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has been named to the Forbes Best Employers for Diversity 2022 list. This prestigious award is presented by Forbes and Statista Inc., a statistics portal and industry ranking provider.

Teleflex Named to Forbes Best Employers for Diversity 2022 List

WAYNE, Pa., April 26, 2022 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Bank of America Securities 2022 Healthcare Conference at the Encore Hotel in Las Vegas, Nevada, on Tuesday, May 10, 2022, at 11:20 a.m. (PT).

Teleflex to Present at the Bank of America Securities 2022 Healthcare Conference

Teleflex (TFX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Teleflex (TFX) Expected to Beat Earnings Estimates: Should You Buy?

WAYNE, Pa., April 14, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its first quarter 2022 results, and provide an operational update at 8:00 a.m. Eastern Time on Thursday, April 28, 2022.

Teleflex Announces First Quarter 2022 Earnings Conference Call Information

Initial Cases Have Now Been Performed in Japan Initial Cases Have Now Been Performed in Japan

Teleflex Announces the Launch of the UroLift® System in Japan for the Treatment of Benign Prostatic Hyperplasia (BPH)

Teleflex offers medical technology products.

Teleflex: Diversified Portfolio Of Medical Devices At A Convenient Stock Price

Teleflex (TFX) continues to face supply-chain challenges and freight logistic delays.

Teleflex (TFX) Hurt by Urolift Cancellations, Cost Woes

WAYNE, Pa., March 09, 2022 (GLOBE NEWSWIRE) -- Thomas Powell, Executive Vice President and Chief Financial Officer, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the KeyBanc Life Sciences & MedTech Investor Forum on Wednesday, March 23, 2022 at 9:45 a.m. (ET).

Teleflex to Present at the KeyBanc Life Sciences & MedTech Investor Forum

WAYNE, Pa., March 02, 2022 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the 43rd Annual Raymond James Institutional Investors Conference at the JW Marriott Orlando Grande Lakes, Orlando, FL, on Tuesday, March 8, 2022, at 9:15 a.m. (ET).

Teleflex to Present at the 43rd Annual Raymond James Institutional Investors Conference

Strong segmental performance in the domestic and international markets is driving Teleflex's (TFX) fourth-quarter top line.

Teleflex (TFX) Q4 Earnings & Revenues Top Estimates, Margins Up

Teleflex Inc. (TFX) CEO Liam Kelly on Q4 2021 Results - Earnings Call Transcript

WAYNE, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the fourth quarter ended December 31, 2021.

Teleflex Announces Fourth Quarter and Full-Year 2021 Financial Results

Results of CTO-PCI IDE Study Demonstrate Procedural Success with Teleflex Specialty Catheters and Coronary Guidewires in Patients Undergoing Chronic Total Occlusion Percutaneous Coronary Interventions Results of CTO-PCI IDE Study Demonstrate Procedural Success with Teleflex Specialty Catheters and Coronary Guidewires in Patients Undergoing Chronic Total Occlusion Percutaneous Coronary Interventions

Teleflex Receives FDA Clearance for Expanded Indication for Specialty Catheter and Coronary Guidewire Use in CTO PCI Procedures

Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Teleflex (TFX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

WAYNE, Pa., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its fourth quarter and full year 2021 financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, February 24, 2022.

Teleflex Announces Fourth Quarter and Full Year 2021 Earnings Conference Call Information

WAYNE, Pa., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 4:30 p.m. (ET).

News for Teleflex Stock (TFX)